1月20日，天眼查融资历程显示，苏州德进生物制药有限公司近日获得"A轮"融资，涉及融资金额数千 万人民币，投资机构为【首发】德进生物完成数千万元A轮融资，凯乘资本担任首席财务顾问。 资料显示，苏州德进生物制药有限公司法定代表人为侯曦凡，成立于2023年，位于苏州市，是一家以从 事医药制造业为主的企业。企业注册资本1707.7176万人民币，并已于2026年完成了A轮，交易金额数千 万人民币。 通过天眼查大数据分析，苏州德进生物制药有限公司共对外投资了1家企业，知识产权方面有商标信息9 条，专利信息1条，此外企业还拥有行政许可13个。 来源：市场资讯 天眼查信息显示，苏州德进生物制药有限公司的股东为：侯曦凡、江志华、上海进赟企业管理合伙企业 （有限合伙）、青岛弘新投资合伙企业（有限合伙）、上海德进隆企业管理有限公司。 ...

资料显示，洛阳华荣生物技术有限公司法定代表人为魏群明，成立于2012年，位于洛阳市，是一家以从 事医药制造业为主的企业。企业注册资本352.936763万人民币，并已于2026年完成了A轮，交易金额超 亿人民币。 通过天眼查大数据分析，洛阳华荣生物技术有限公司共对外投资了1家企业，知识产权方面有商标信息1 条，专利信息41条，此外企业还拥有行政许可63个。 1月20日，天眼查融资历程显示，洛阳华荣生物技术有限公司近日获得"A轮"融资，涉及融资金额超亿 人民币，投资机构为华荣生物完成超亿元A轮融资，专注生物催化技术。 来源：市场资讯 天眼查信息显示，洛阳华荣生物技术有限公司的股东为：洛阳森佰生物技术有限责任公司、魏群明、洛 阳市产业发展基金合伙企业（有限合伙）、洛阳森捷生物技术合伙企业（有限合伙）、洛阳森荣生物技 术合伙企业（有限合伙）。 ...

岁末年初，广东国资国企决胜"十四五"收官、迎接"十五五"开局动力十足。过去五年，面对复杂因素交织的内外部环境，国资 国企以强化战略支撑为根基，以推动产业向新为方向，以深化改革为动力，构筑韧性穿越周期，在交出一份"广东答卷"的同时 阔步迈向下一个五年。 当广东经济连跨14万亿大关、GDP连续36年位居全国第一，广东国资国企发挥了"压舱石""火车头"作用——截至2024年底，广 东省地方国资监管企业资产总额18.72万亿元、营业收入3.8万亿元、利润总额946.18亿元，完成固定资产投资8653.23亿元。 惠来电厂扩建工程5号机组投入商业运营（受访者供图） 南方财经记者伍素文 广州报道 列车疾驰，随着粤东西时速350公里的两大高铁通道全面贯通，广州至湛江、汕头加入"1.5小时高铁圈"；设备轰鸣，广东省能源 集团所属靖海发电公司负责建设的惠来电厂扩建工程5号机组投入商业运营，为粤东发展注入新动能...... 五年长卷铺展。从广袤田野到智能车间，从科技会展到资本市场，国资国企在不同领域协同发力、汇聚成势，持续增强战略功 能与核心价值，积极开拓增长"第二曲线"，推动"十四五"规划高质量收官，为新征程积蓄磅礴势能。 超 ...

Group 1: Government Policies and Economic Measures - The Ministry of Finance announced multiple policies to enhance personal consumption loan interest subsidies and implement a special guarantee plan for private investment [1] - The fiscal deficit, total debt, and overall expenditure will maintain necessary levels through 2026, ensuring that overall expenditure "only increases" and key areas are "only strengthened" [1][2] - A tax and fee exemption policy for community service industries, including elderly care and childcare, will be effective from January 1, 2026, to December 31, 2027 [2] Group 2: Company News and Financial Performance - Hikvision reported a revenue of 92.518 billion yuan for 2025, with a slight year-on-year increase of 0.02%, while net profit grew by 18.46% to 14.188 billion yuan [5] - Tongfu Microelectronics expects a net profit of 1.1 billion to 1.35 billion yuan for 2025, representing a growth of 62.34% to 99.24% year-on-year [5] - Puxin Technology anticipates a net profit of 2.3 billion to 2.4 billion yuan for 2025, marking a growth of 93.18% to 101.58% year-on-year [5] - Aifan Transmission plans to acquire 87.07% of Beijing Heli Technology Co., which is expected to constitute a major asset restructuring [6][7] - Aifan Transmission's acquisition is expected to enhance its overall strength and improve business performance [7] Group 3: Clinical and Pharmaceutical Developments - Baili Tianheng received approval for its innovative drug application for a dual-target antibody ADC for treating recurrent or metastatic esophageal squamous cell carcinoma, marking a significant milestone in clinical development [8] - Aibo Medical plans to acquire at least 51% of Demai Medical, a high-tech enterprise, to expand into the sports health sector [9][10] Group 4: Market and Investment Insights - CITIC Securities reports that the recent pullback in the securities sector does not indicate the end of the market rally, suggesting potential upward paths for the sector [11]

Group 1: Earnings Forecasts - Huabang Health expects a net profit of 660 million to 730 million yuan for 2025, recovering from a loss of 299 million yuan in the previous year, driven by improvements in its agricultural chemical materials sector and steady growth in its pharmaceutical and tourism segments [2] - Kangda New Materials anticipates a net profit of 125 million to 135 million yuan for 2025, compared to a loss of 246 million yuan last year, primarily due to significant sales growth in adhesive and specialty resin products, particularly in the wind power sector [2] - Longxin Technology forecasts a net profit of 100 million to 150 million yuan for 2025, recovering from a loss of 250 million yuan, with improvements in its energy digitalization business and reduced losses in its new energy sector [3] - Hualu Bio expects a net profit of 100 million to 130 million yuan for 2025, recovering from a loss of 47.57 million yuan, attributed to increases in both sales price and volume [3] - Jiuxi Software predicts a net profit of 40 million to 60 million yuan for 2025, recovering from a loss of 156 million yuan, supported by AI technology enhancements and market expansion strategies [3] Group 2: Major Corporate Developments - Liou Co. has completed its stock suspension review and will resume trading on January 21, 2026, confirming that its business operations remain normal and no significant undisclosed matters exist [4] - Hikvision reported total revenue of 92.518 billion yuan for 2025, a slight increase of 0.02%, with a net profit of 14.188 billion yuan, up 18.46%, driven by strategic adjustments and improved cash flow management [6] - JianTou Energy expects a net profit of approximately 1.877 billion yuan for 2025, a significant increase of about 253.38% from the previous year, due to optimized coal resource allocation and cost management [6] Group 3: Investment and Mergers - Aibo Medical plans to acquire at least 51% of Demai Medical to gain control, aiming to leverage its R&D advantages in the sports health sector [19] - Yifan Transmission intends to purchase 87.07% of Beijing Helishi Motor Technology Co., which will become a subsidiary upon successful completion of the transaction [16] - Guangdong Hongtu plans to invest up to 95 million yuan to establish a subsidiary in Thailand for automotive parts production and sales [20] Group 4: Stock Performance and Changes - Huicheng Environmental's major shareholder plans to increase their stake in the company by investing between 25 million and 50 million yuan within six months [22] - Liou Co. will resume trading after completing its stock suspension review, indicating stability in its operations [24] - Kailong High-Tech and Debang Co. have been suspended from trading, indicating potential issues or developments requiring further clarification [25]

Core Viewpoint Several companies listed on the New Third Board have announced significant developments regarding their plans to go public on the Beijing Stock Exchange, including fundraising initiatives and entering the counseling phase for their listings. Group 1: Listing Progress - Dongxiao Biological Technology Co., Ltd. has approved a proposal to apply for public stock issuance and listing on the Beijing Stock Exchange, aiming to raise funds for projects including functional sugar alcohol industrial upgrades and high-value amino acid construction [2] - Shuoen Network Technology Co., Ltd. has entered the counseling phase for its listing application after signing a counseling agreement with Shenwan Hongyuan Securities [3] - Jinli Transmission Technology Co., Ltd. has also entered the counseling phase for its listing application, focusing on micro-motor and micro-transmission system development [4] - Zetian Chunlai Technology Co., Ltd. has begun its counseling phase for listing after submitting its application materials to the regulatory authority [5] - Huaxin Kecai Technology Co., Ltd. has entered the counseling phase for its listing application, specializing in wind measurement laser radar technology [6] - Haihong Hydraulic Technology Co., Ltd. has signed a counseling agreement for its listing application and submitted the necessary materials [7] Group 2: Major Contracts - Suizhong Technology Co., Ltd. has successfully won a bid for a digital asset management and operation system project with a central enterprise, with a total contract value of RMB 1.39 million [12] Group 3: External Investments - Hainan Shanxiang Times Education Technology Co., Ltd. plans to increase capital in its wholly-owned subsidiary, Henan Shanxiang Education Consulting Co., Ltd., introducing new investors [13] - Suzhou Feichi Environmental Technology Co., Ltd. intends to participate in the capital increase of Suzhou Ouchi Intelligent Technology Co., Ltd. [15] - Shaanxi Ruike New Materials Co., Ltd. plans to establish a wholly-owned subsidiary in Zhuhai with a registered capital of RMB 20 million [16] - Chengdu Sihan Technology Co., Ltd. aims to set up a wholly-owned subsidiary focused on technology research and product innovation in non-core business areas [17] Group 4: Financial Management - Suzhou Jinqian New Materials Co., Ltd. plans to invest up to RMB 50 million of idle funds in low-risk financial products to enhance fund utilization [18] - Zhejiang Apollo Sports Technology Co., Ltd. intends to use idle funds to purchase short-term financial products, with a maximum balance of RMB 300 million [19] - Huayou Technology Co., Ltd. plans to invest up to RMB 30 million of idle funds in short-term financial products [20] - Shanghai Songke Automation Co., Ltd. aims to use idle funds for purchasing structured deposits and financial products, with a limit of RMB 70 million [21] - Shiyan Precision New Power Technology Co., Ltd. plans to use up to RMB 80 million of idle funds for cash management through financial products [22][23] Group 5: Annual Performance - Shanghai Jinghong International Logistics Co., Ltd. reported a net profit increase of 16.90% for the year 2025, despite a slight decrease in revenue [25]

证券日报网讯1月20日，九洲药业（603456）在互动平台回答投资者提问时表示，公司CDMO业务覆盖 全球主要医药市场，服务的客户主要在欧洲、亚太地区。目前海外业务占比80%左右。公司与客户主要 通过签订单次或年度采购合同(协议)来开展合作，具体业务模式与区域详情可参阅公司于上海证券交易 所网站披露的定期报告。 ...

Group 1: Policy Updates - The implementation period for the personal consumption loan interest subsidy policy has been extended to the end of 2026, effective from January 1, 2026[2] - The subsidy policy now includes credit card installment payments and removes the previous limits on single transactions and cumulative subsidies below 50,000 yuan[2] - The subsidy cap for new loans in the service industry has been raised to 10 million yuan, with a 1% annual subsidy rate, shared by central and provincial finances at a 9:1 ratio[2] Group 2: Market Performance - On January 20, 2026, the North Exchange 50 index fell by 2.00%, while the ChiNext index decreased by 1.79% and the Shanghai Composite index dropped by 0.01%[12] - The North Exchange had 288 constituent stocks with an average market capitalization of 3.224 billion yuan and a trading volume of 26.629 billion yuan, an increase of 2.599 billion yuan from the previous trading day[12] - Among individual stocks, Meibang Technology, Liujin Technology, and Yinen Power saw increases of 29.94%, 16.22%, and 11.14% respectively, while Qifeng Precision, Litong Technology, and Rongyi Precision experienced declines of 10.14%, 8.59%, and 6.81%[13] Group 3: Industry News - The National Development and Reform Commission plans to enhance the effectiveness of the "Two New" policy in 2026, which has already driven over 1 trillion yuan in equipment updates and 2.6 trillion yuan in sales from old-for-new exchanges in 2025[9] - A new national standard for biodegradable plastic bags will be implemented on January 1, 2027, increasing the degradation rate requirement from 60% to 90%[11]

Core Viewpoint - China Resources Pharmaceutical Group Limited is a leading comprehensive pharmaceutical company in China, ranking among the top three in the industry, with a compound annual growth rate (CAGR) of 7.5% in revenue from 2019 to 2024 [1] Group 1: Pharmaceutical Manufacturing and OTC Business - The company is the largest OTC manufacturer in China, focusing on consumer health products (CHC), with traditional Chinese medicine and health products accounting for nearly 60% of revenue by mid-2025 [1] - The pharmaceutical business is expected to grow at a CAGR of 10.4% from 2022 to 2024, driven by both organic growth and acquisitions [2] - By mid-2025, the revenue from OTC traditional Chinese medicine and chemical OTC products reached 8.7 billion yuan and 2.5 billion yuan, respectively, making up 45% of the pharmaceutical business revenue [1] Group 2: Business Expansion through Acquisitions - The company expanded its business scope through acquisitions, including a 43% stake in Jiangzhong Pharmaceutical in February 2019, enhancing its position in the traditional Chinese medicine sector [2] - Acquisitions of 28% stakes in Kunming Pharmaceutical and Tasly Pharmaceutical in December 2022 and March 2025, respectively, further solidified its leadership in the traditional Chinese medicine industry [2] - The company entered the blood products sector by acquiring a 29% stake in Boya Bio-Pharmaceutical in November 2021 and expanded into medical devices with the acquisition of Nanger Technology in February 2025 [2] Group 3: Pharmaceutical Distribution - The company ranks third in the pharmaceutical distribution industry, with revenue reaching 110 billion yuan in the first half of 2025, following China National Pharmaceutical Group and Shanghai Pharmaceuticals [3] - The distribution business generated 108.3 billion yuan in revenue in the first half of 2025, with medical device revenue growing by 8% to 18 billion yuan [3] - Retail revenue reached 5.5 billion yuan in the first half of 2025, reflecting an 11% year-on-year growth, supported by the establishment of specialized pharmacies and a new retail system [3] Group 4: Financial Projections and Valuation - The company is projected to achieve net profits attributable to ordinary shareholders of 3.49 billion yuan, 3.76 billion yuan, and 4.05 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 4.0%, 7.9%, and 7.7% [3] - A price-to-earnings (PE) ratio of 8.7 times is assigned for 2026, corresponding to a market value of 35.3 billion Hong Kong dollars, indicating a 24% upside potential from the current market value of 28.5 billion Hong Kong dollars [3]

Core Insights - In November 2025, China's import volume of medicinal materials and pharmaceuticals was 24,400 tons, representing a year-on-year decrease of 13.1% [1] - The import value for the same period was $4.111 billion, showing a slight decline of 0.2% year-on-year [1] - Conversely, the export volume of medicinal materials and pharmaceuticals reached 160,000 tons, marking a year-on-year increase of 8.6% [1] - The export value was $2.374 billion, reflecting a year-on-year growth of 7.8% [1] Import and Export Analysis - The decline in import volume and value indicates potential challenges in the domestic market for medicinal materials and pharmaceuticals [1] - The increase in export volume and value suggests a growing demand for Chinese medicinal products in international markets [1] - The contrasting trends in imports and exports may highlight shifts in supply chain dynamics and market opportunities for stakeholders in the industry [1]